Arax Advisory Partners’s Lifecore Biomedical LFCR Stock Holding History

Arax Advisory Partners’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.29K	Buy	+246	New	+$1.24K	﹤0.01%	4896
2026 Q1	–	Sell	-5	Closed	-$41	–	4103
2025 Q4	$41	Buy	+5	New	+$37	﹤0.01%	3952

Other funds holding LFCR

Wynnefield Capital New York $145M AUM 14.57% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $40.6M AUM 156.55% 1-Year Est. Return

GRIM

Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return

325 Capital New York $419M AUM 75.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

QOP

Quinn Opportunity Partners Charlottesville, Virginia $2.16B AUM 28.56% 1-Year Est. Return

Arax Advisory Partners's LFCR Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Lifecore Biomedical (LFCR) in Q2 2026: 246 shares worth $1.29K. The stake represents ﹤0.01% of the portfolio and ranks #4896 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in LFCR as recently as Q4 2025.

Arax Advisory Partners first reported a position in LFCR in Q4 2025 and has held it in 2 quarters since. 99 funds tracked by Wall St. Rank hold LFCR as of Q2 2026.

Arax Advisory Partners held 246 shares of Lifecore Biomedical worth $1.29K as of Q2 2026.
Lifecore Biomedical was a new Arax Advisory Partners position in Q2 2026.
Lifecore Biomedical made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4896 holding.
Arax Advisory Partners first reported a position in Lifecore Biomedical in Q4 2025 and has held it in 2 quarters since.
99 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.